Epidemiology, health policy and outcomes
Christina Downey, MD, RhMSUS
Loma Linda University Medical Center
Redlands, CA, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Amanda Grimm Wiegrefe, MSc
American College of Rheumatology
Washington, DC, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Lennie McDaniel, JD
American College of Rheumatology
Washington, DC, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
One of the primary benefits of ACR/ARP membership is the advocacy efforts expended on behalf of physicians, care team members, and patients to steer the public on your behalf. From the U.S. Congress and federal regulatory agencies, to your state capitol and even private payers, the ACR has professional staff and dedicated volunteers lobbying for the interests of the rheumatology community. This session will introduce those individuals and update attendees on current public policy that may impact their work, including cuts to Medicare reimbursement, prior authorization reform, step therapy reform, prescription drug pricing, supporting the medical workforce, adjusting to biosimilars, the evolution of telehealth, and federal funding for biomedical research.
Speaker: Christina Downey, MD, RhMSUS – Loma Linda University Medical Center
Speaker: Lennie McDaniel, JD – American College of Rheumatology
Speaker: Amanda Grimm Wiegrefe, MSc – American College of Rheumatology